Press Releases

No. 03 | 16. January 2019 | by Eck

Vaccination as a therapy: Experimental vaccine against cervical cancer successfully tested in mice

Computer-generated simulation of a HPV

Scientists from the German Cancer Research Center (DKFZ) have developed an experimental vaccine to fight cervical cancer caused by human papillomaviruses (HPV). This has already been accomplished successfully in mice. Tumors regressed in half of the vaccinated animals. The scientists' goal is to develop a therapeutic vaccine for people who are already suffering from cancer or cancer precursors and, thus, no longer benefit from preventive vaccination.

read more

No. 02c2 | 15. January 2019

“Life Time” – European research for a healthier future

© Spencer Phillips, EMBL-EBI

Our body's cells are constantly changing. But which of these changes are healthy developments and which lead to serious diseases? This is what LifeTime, a new transnational and interdisciplinary initiative of leading European researchers, aims to discover. The consortium is jointly coordinated by the Max Delbrück Center in Berlin and the Institut Curie in Paris, with the Helmholtz Association and the CNRS. Scientists from the DKFZ are also involved in the consortium. Life Time has now cleared an important hurdle: The consortium will be given one million euros and one year to develop a plan to embed its vision for a healthier future within the European research and innovation landscape.

read more

No. 02 | 08. January 2019 | by Rei

New vaccine strategy against Epstein Barr virus

Epstein Barr viruses in blood vessels
© Adobe Stock/DKFZ

The Epstein Barr viruses (EBV) are very common and in most cases, an infection causes no harm. However, sometimes the outcome is a serious disease. There is no effective immunization protection against EBV so far, because the pathogen is very difficult to get hold of. Scientists from the German Cancer Research Center (DKFZ) in Heidelberg have now developed a new strategy for developing a vaccine against EBV that will simultaneously prepare the immune system for different stages of the pathogen. In this way, the researchers are convinced to have made major progress towards developing a vaccine against EBV.

read more

No. 01 | 07. January 2019 | by Mat

COMPASS: The guide to new therapies for children with cancer

The COMPASS project aims to identify new ways of treating childhood cancers
© Adobe Stock / Tobias Machhaus

Through a targeted combination of molecular and microscopy-based techniques, researchers aim to identify new treatment approaches for children with cancer. The Hopp Children's Cancer Center Heidelberg (KiTZ) coordinates the project, which is funded by the European consortium ERA PerMed with 1.5 million euros and involves scientific institutions from France, the Netherlands, Finland and Hungary in addition to the KiTZ.
The "Hopp Children's Cancer Center Heidelberg" (KiTZ) is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and Heidelberg University.

read more

No. 71 | 20. December 2018 | by Rei

An important step for regenerative medicine: Human blood cells can be directly reprogrammed into neural stem cells

© M.C. Thier/DKFZ

Scientists from the German Cancer Research Center (DKFZ) and the stem cell institute HI-STEM* in Heidelberg have succeeded for the first time in directly reprogramming human blood cells into a previously unknown type of neural stem cell. These induced stem cells are similar to those that occur during the early embryonic development of the central nervous system. They can be modified and multiplied indefinitely in the culture dish and can represent an important basis for the development of regenerative therapies.

read more

No. 65 | 06. December 2018 | by Koh

Leibniz Prize for Hans-Reimer Rodewald

Hans-Reimer Rodewald
© Jutta Jung/DKFZ

Hans-Reimer Rodewald from the German Cancer Research Center (DKFZ) has received the 2019 Gottfried Wilhelm Leibniz Prize, which is the most important research funding award in Germany. Rodewald's work focuses on the question of how various types of immune cells develop from stem cells and together form a functioning immune system.

read more

No. 68 | 11. December 2018

Computer Model to Predict Prostate Cancer Progression

© Fotolia

An international team of cancer researchers from Germany and Denmark have used cancer patient data to develop a computer model that can predict the course of disease for prostate cancer. The model is currently being implemented at a prostate cancer clinic in Germany. The researchers have also found the enzyme that appears to trigger some of the first mutations in prostate cancer.

read more

No. 67 | 11. December 2018 | by Koh

High distinction for stem cell researcher Andreas Trumpp

Andreas Trumpp
© Roman Jowanowitsch/DKFZ

This year's State Research Prize of Baden-Württemberg awarded for outstanding achievements in applied research goes to Andreas Trumpp from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM). Theresia Bauer, State Minister of Science, Research and the Arts, presented the award, which carries a monetary prize of €100.000, at a festive ceremony on December 10, 2018.

read more

No. 66 | 10. December 2018 | by Mat

The sleeping beauty among brain tumors

Pilocytic astrocytoma (PA) is a type of brain tumor common in childhood
© KiTZ

Scientists from the Hopp Children's Tumor Center Heidelberg (KiTZ), together with two other teams from the German Cancer Association (DKTK) and researchers from the UK, have shown that a group of inflammatory messengers slows down or even stops the growth of certain brain tumor cells. This molecular mechanism could be the key to new therapeutic approaches.
The "Hopp Children's Cancer Center Heidelberg" (KiTZ) is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and Heidelberg University.

read more

No. 65c | 06. December 2018 | by Koh

New Ways to Look at Protein-RNA Networks

A network of interacting RNAs and proteins is active in each of our cells.
© Fotolia

For their vital tasks, all RNA molecules in our cells require proteins as binding partners. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and colleagues from the European Molecular Biology Laboratory (EMBL) have developed the first method with which they can analyze the composition of the entire RNA-protein network of the cell. The new method has now been published in the scientific journal "Cell".

read more


Subscribe to our RSS-Feed.

to top